ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
118.85
-0.51 (-0.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close119.36
Open119.97
Bid0.00 x 800
Ask0.00 x 900
Day's Range118.70 - 120.78
52 Week Range51.05 - 124.40
Volume348,156
Avg. Volume546,057
Market Cap3.514B
Beta1.84
PE Ratio (TTM)N/A
EPS (TTM)-13.00
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est127.38
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPT

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realist7 days ago

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderate for ICPT with between 5 and 10% of shares outstanding currently on loan. The $1.27 billion in inflows that ETFs holding ICPT received over the last one-month is a decline from earlier in the period and among the weakest of the past year.

  • Analyzing Axovant Sciences’ Valuation Metrics
    Market Realist8 days ago

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.

  • 3 Top Stocks for Investing in Pharma's Next $35 Billion Market
    Motley Fool9 days ago

    3 Top Stocks for Investing in Pharma's Next $35 Billion Market

    Here's why these three biotechs could come out ahead in the race to tackle a leading cause of liver failure.

  • Here's Why Intercept Pharmaceuticals Jumped 22.7% in August
    Motley Fool9 days ago

    Here's Why Intercept Pharmaceuticals Jumped 22.7% in August

    Its Ocaliva is selling well enough as investors wait for more clinical trial data next year.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit14 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on September 5.

  • GlobeNewswire23 days ago

    Intercept to Present at Upcoming Investor Conferences

    NEW YORK, Aug. 29, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Array BioPharma and Intercept Pharmaceuticals

    On Friday, Fed Chairman Jerome Powell is scheduled for a speech at the Kansas City Fed’s annual summer retreat. The Nasdaq Composite Index increased 0.49 percent to close at 7,859.17. Investment strategist at Edward Jones, Kate Warne said, “I think that this is optimism on at least some partial resolution of the trade negotiations as investors are expecting progress [on that front].” “If we reach new highs that’s great but I think it would be a reflection of the positive underlying fundamentals of very positive earnings growth and modest interest rates,” Warne added.

  • Array BioPharma Posted Net Loss of $52.4 Million in Q4
    Market Realistlast month

    Array BioPharma Posted Net Loss of $52.4 Million in Q4

    On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.

  • Is Intercept Pharmaceuticals, Inc. a Buy?
    Motley Foollast month

    Is Intercept Pharmaceuticals, Inc. a Buy?

    This company's leading a race that's drawn a lot of competition.

  • What Analysts Recommend for Array BioPharma Stock
    Market Realistlast month

    What Analysts Recommend for Array BioPharma Stock

    Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ICPT earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Intercept Pharmaceuticals Inc Earnings Call

  • Investopedialast month

    4 Biotech Stocks That May Fall By as Much as 13%

    Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.

  • Puma Biotechnology: Recent Developments and Recommendations
    Market Realistlast month

    Puma Biotechnology: Recent Developments and Recommendations

    In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.

  • How Puma Biotechnology Performed in Q2 2018
    Market Realistlast month

    How Puma Biotechnology Performed in Q2 2018

    Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.

  • 2 Growth Stocks That Could Make You Rich
    Motley Foollast month

    2 Growth Stocks That Could Make You Rich

    Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.

  • Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6
    Market Realistlast month

    Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6

    On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist ...

  • Why Intercept Pharmaceuticals Stock Is Moving Higher Today
    Motley Foollast month

    Why Intercept Pharmaceuticals Stock Is Moving Higher Today

    Wall Street is warming up to this mid-cap drugmaker.

  • Benzinga2 months ago

    Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) reported top- and bottom-line beats last week that prompted two Street analysts to upgrade the stock. The Rating Goldman Sachs analyst Salveen Richter upgraded ...

  • Barrons.com2 months ago

    Small Biotechs See Big Gains as Bluebird, Intercept Fly

    Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price.  The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years.  Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.

  • Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers
    Zacks2 months ago

    Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

    Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.